pharma · Recipients of allogeneic stem cell transplantation
AstraZeneca
Astra Zeneca AB
Astra Zeneca AB is a pharma organization headquartered in EU. Primary therapeutic focus areas include Recipients of allogeneic stem cell transplantation. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and
cambridge, GB HQ
79,242 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- cambridge, GB
- Employees
- 79,242
- Programs
- 1
- Drugs
- 8
- Patents
- 25
ALLO-HPV
Phase 2 · small molecule · Recipients of allogeneic stem cell transplantation
ALLO-HPV for Recipients of allogeneic stem cell transplantation is a Phase 2 program (small_molecule) at Astra Zeneca AB with 1 ClinicalTrials.gov record(s).
Internal code ALLO-HPV
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Astra Zeneca AB
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Recipients of allogeneic stem cell transplantation
- Status
- active
- Trials
- 1